Risks of COVID-19-related hospitalisation and mortality among individuals with mental disorders following BNT162b2 and CoronaVac vaccinations: A case-control study

被引：2

作者：

Yiu, Hei Hang Edmund ^{[1
]}

Yan, Vincent K. C. ^{[1
]}

Wei, Yue ^{[1
]}

Ye, Xuxiao ^{[1
]}

Huang, Caige ^{[1
]}

Castle, David J. ^{[2
,3
]}

Chui, Celine S. L. ^{[4
,5
,6
]}

Lai, Francisco T. T. ^{[1
,4
,7
]}

Li, Xue ^{[1
,4
,8
]}

Wong, Carlos K. H. ^{[1
,4
,7
]}

Wan, Eric Y. F. ^{[1
,4
,7
]}

Wong, Ian C. K. ^{[1
,4
,9
,10
,13
]}

Chan, Esther W. ^{[1
,4
,11
,12
,13
]}

机构：

[1] Univ Hong Kong, LKS Fac Med, Ctr Safe Medicat Practice & Res, Dept Pharmacol & Pharm, Hong Kong, Peoples R China

[2] Univ Tasmania, Dept Psychiat, Hobart, Tas, Australia

[3] Statewide Mental Hlth Serv, Ctr Mental Hlth Serv Innovat, Hobart, Tas, Australia

[4] Hong Kong Sci & Technol Pk, Lab Data Discovery Hlth D 2 4H, Hong Kong, Peoples R China

[5] Univ Hong Kong, LKS Fac Med, Sch Nursing, Hong Kong, Peoples R China

[6] Univ Hong Kong, LKS Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China

[7] Univ Hong Kong, LKS Fac Med, Sch Clin Med, Dept Family Med & Primary Care, Hong Kong, Peoples R China

[8] Univ Hong Kong, LKS Fac Med, Sch Clin Med, Dept Med, Hong Kong, Peoples R China

[9] Aston Univ, Aston Pharm Sch, Birmingham, England

[10] Govt Hong Kong SAR, Expert Comm Clin Events Assessment Following COVID, Dept Hlth, Hong Kong, Peoples R China

[11] Univ Hong Kong, Shenzhen Hosp, Dept Pharm, Shenzhen, Peoples R China

[12] Univ Hong Kong, Shenzhen Inst Res & Innovat, Shenzhen, Peoples R China

[13] Univ Hong Kong, LKS Fac Med, Ctr Safe Medicat Practice & Res, Dept Pharmacol & Pharm,Gen Off,Pokfulam, L02-56 2-F,Lab Block, 21 Sassoon Rd, Hong Kong, Peoples R China

来源：

PSYCHIATRY RESEARCH | 2023年 / 329卷

关键词：

Vaccine effectiveness; COVID-19; Vaccination; Hospitalisation; Mortality; Mental disorders; VACCINE HESITANCY;

D O I：

10.1016/j.psychres.2023.115515

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Concerns have been raised regarding potential weaker vaccine immunogenicity with higher immune suppression for individuals with pre-existing mental disorders. Yet, data on the effectiveness of COVID-19 vaccinations among this vulnerable population are limited. A case-control study was conducted to investigate the risks of COVID-19-related hospitalisation and mortality among individuals with mental disorders following one to three doses of BNT162b2 and CoronaVac vaccinations in Hong Kong. Data were extracted from electronic health records, vaccination and COVID-19 confirmed case records. Conditional logistic regression was applied with adjustment for comorbidities and medication history. Subgroup analyses were performed with stratification: by age (< 65 and >= 65) and mental disorders diagnosis (depression, schizophrenia, anxiety disorder, and bipolar disorder). Two doses of BNT162b2 and CoronaVac significantly reduced COVID-19-related hospitalisation and mortality. Further protection for both outcomes was provided after three doses of BNT162b2 and CoronaVac. The vaccine effectiveness magnitude of BNT162b2 was generally higher than CoronaVac, but the difference diminished after the third dose. Individuals with mental disorders should be prioritised in future mass vaccination programmes of booster doses or bivalent COVID-19 vaccines. Targeted strategies should be developed to resolve the reasons behind vaccine hesitancy among this population and increase their awareness on the benefits of vaccination.

引用

页数：9

共 40 条

[1] How long does covid-19 immunity last? [J].